期刊文献+

炙甘草汤合生脉散加减治疗非瓣膜性房颤疗效及对心功能和血清Ps、ICAM-1、tPA水平的影响 被引量:4

Curative Effect of Using Zhigancao Decoction Combined with Modified Shengmai Powder and Western Medicine in the Treatment of Non-valvular Atrial Fibrillation and the Influences on Cardiac Function, Serum P-selectin, ICAM-1 and tPA Levels
原文传递
导出
摘要 目的:探讨炙甘草汤合生脉散加减联合西药对非瓣膜性心房颤动(NVAF)患者疗效、心功能及血清P-选择素(Ps)、细胞间粘附分子-1(ICAM-1)、组织型纤溶酶原激活物(tPA)水平的影响。方法:选取2020年9月~2021年9月在本院收治的72例NVAF患者,采用随机数字表法分为观察组与对照组各36例,对照组采取西药治疗,观察组在对照组的基础上联合炙甘草汤合生脉散加减治疗,持续治疗4周后比较两组患者临床疗效。观察并记录两组中医证候积分及心功能指标[左室舒张末内径(LVEDD)、左室射血分数(LVEF)、N末端B型尿钠肽原(NT-proBNP)]、血清Ps、ICAM-1、tPA水平的差异变化,并记录两组不良反应发生率。结果:观察组的临床治疗总有效率为91.67%,高于对照组的72.22%(P<0.05)。治疗后,观察组中医证候积分低于对照组(P<0.05),观察组LVEDD、NT-proBNP水平低于对照组(P<0.05),LVEF水平高于对照组(P<0.05),观察组血清Ps、ICAM-1水平低于对照组(P<0.05),tPA水平高于对照组(P<0.05)。两组不良反应发生率无明显差异(P>0.05)。结论:炙甘草汤合生脉散加减联合西药治疗NVAF,可减轻患者血液黏附分子水平,改善患者心功能,提高临床疗效。 Objective:To explore the curative effect of Zhigancao Decoction combined with Modified Shengmai Powder and western medicine for patients with non-valvular atrial fibrillation(NVAF)and the influences on cardiac function,levels of serum P-selectin(Ps),intercellular adhesion molecule-1(ICAM-1)and tissue plasminogen activator(tPA).Methods:A total of 72 patients with NVAF admitted to the hospital were enrolled between September 2020 and September 2021.According to random number table method,they were divided into an observation group and a controlled group,36 cases in each group.The controlled group was treated with western medicine,while the observation group was additionally treated with Zhigancao Decoction combined with Modified Shengmai Powder.After 4 weeks of continuous treatment,clinical curative effect between the two groups was compared.The differences in scores of TCM syndromes,cardiac function indexes[left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),N-terminal B-type natriuretic peptide(NT-proBNP)],and levels of serum Ps,ICAM-1 and tPA in the two groups were observed and recorded.The incidence of adverse reactions in both groups was recorded.Results:The total response rate of clinical treatment in the observation group was higher than that in the controlled group(91.67%vs 72.22%)(P<0.05).After treatment,scores of TCM syndromes in the observation group were lower than those in the controlled group(P<0.05),levels of LVEDD and NT-proBNP were lower than those in the controlled group(P<0.05),LVEF level was higher than that in the controlled group(P<0.05),levels of serum Ps and ICAM-1 were lower than those in the controlled group(P<0.05),and tPA level was higher than that in the controlled group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Zhigancao Decoction combined with Modified Shengmai Powder and western medicine can reduce levels of blood adhesion factors,improve cardiac function and clinical curative effect in NVAF patients.
作者 吴文虎 何喜民 崔小红 冯旭霞 尹培永 赵营营 WU Wenhu;HE Ximin;CUI Xiaohong(Departmen of the Second Internal Medicine,Sanya Hospital of Traditional Chinese Medicine,Sanya Hainan 572000,China)
出处 《四川中医》 2022年第10期73-76,共4页 Journal of Sichuan of Traditional Chinese Medicine
关键词 炙甘草汤 生脉散 非瓣膜性心房颤动 心功能 P-选择素 细胞间粘附分子-1 组织型纤溶酶原激活物 Zhigancao Decoction combined with Shengmai Powder Non-valvular atrial fibrillation Cardiac function Pselectin Intercellular adhesion molecule-1 Tissue plasminogen activator
  • 相关文献

参考文献7

二级参考文献53

  • 1刘为民,姜锐,丁沙沙,傅威,王淑勤,李雪,康婧,吴东宁,刘波,毛文超,何丽云,刘保延.稳心颗粒治疗心房颤动的随机对照试验质量评价[J].中国中药杂志,2012,37(1):109-114. 被引量:14
  • 2黄维义,李刚,严丽,彭永权,罗兴林.华法林在慢性心房颤动抗凝治疗中的应用[J].临床心血管病杂志,2006,22(5):276-278. 被引量:24
  • 3Hankey GJ,Patel MR,Stevens SR,et al.Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack:a subgroup analysis of ROCKET A F[J].Lancet Neurol,2012,11(4):315-322.
  • 4Eikelboom JW.Selective factor Xa inhibition for thrombop rophylaxis[J].Lancet,2008,372(9632):312-391.
  • 5Gage BF,Waterman AD,Shannon W,et al.Validation of clinical classification schemes for predicting stroke:results from the National Registry of Atrial Fibrillation[J].JAMA,2001,285:2864-2870.
  • 6Fatkin D,Kelly RP,Feneley MP.Relations between Left atrial appendage blood flow velocity,spontaneous echocardiographic contrast and thromboembolic risk in vivo[J].J Am Coll Cardiol,1994,23(4):961-969.
  • 7Black IW,Chesterman CN,Hopkins AP,et al.Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation[J].J Am Coll Cardiol,1993,21(2):451-457.
  • 8Kamiyama N.Expression of cell adhesion molecules and the appearance of adherent leukocy-tes on the left atrial endothelium with atrial fibrillation:rabbit experimental model[J].Jpn C-ire J,1998,62(11):837-843.
  • 9Perzborn E,Strassburger J,Wilmen A,et al.In vitro and in vivo studies of the novel antithrombotic agent BAY59-7939 an oral,direct factor Xa inhibitor[J].J Thromb Haemost,2005,3(3):514-521.
  • 10Hass S.New oral Xa andⅡa inhibition:updates and clinical trial results[J].J Thromb Thrombolysis,2008,25(1):52-60.

共引文献201

同被引文献40

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部